1
|
Alfano L, Iannuzzi CA, Barone D, Forte IM, Ragosta MC, Cuomo M, Mazzarotti G, Dell'Aquila M, Altieri A, Caporaso A, Roma C, Marra L, Boffo S, Indovina P, De Laurentiis M, Giordano A. CDK9-55 guides the anaphase-promoting complex/cyclosome (APC/C) in choosing the DNA repair pathway choice. Oncogene 2024; 43:1263-1273. [PMID: 38433256 DOI: 10.1038/s41388-024-02982-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2023] [Revised: 02/08/2024] [Accepted: 02/13/2024] [Indexed: 03/05/2024]
Abstract
DNA double-strand breaks (DSBs) contribute to genome instability, a key feature of cancer. DSBs are mainly repaired by homologous recombination (HR) and non-homologous end-joining (NHEJ). We investigated the role of an isoform of the multifunctional cyclin-dependent kinase 9, CDK9-55, in DNA repair, by generating CDK9-55-knockout HeLa clones (through CRISPR-Cas9), which showed potential HR dysfunction. A phosphoproteomic screening in these clones treated with camptothecin revealed that CDC23 (cell division cycle 23), a component of the E3-ubiquitin ligase APC/C (anaphase-promoting complex/cyclosome), is a new substrate of CDK9-55, with S588 being its putative phosphorylation site. Mutated non-phosphorylatable CDC23(S588A) affected the repair pathway choice by impairing HR and favouring error-prone NHEJ. This CDK9 role should be considered when designing CDK-inhibitor-based cancer therapies.
Collapse
Affiliation(s)
- Luigi Alfano
- Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori-Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)-Fondazione G. Pascale, Napoli, Italy.
| | - Carmelina Antonella Iannuzzi
- Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori-Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)-Fondazione G. Pascale, Napoli, Italy
| | - Daniela Barone
- Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori-Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)-Fondazione G. Pascale, Napoli, Italy
| | - Iris Maria Forte
- Breast Unit, Istituto Nazionale Tumori-Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)-Fondazione G. Pascale, Napoli, Italy
| | | | - Maria Cuomo
- Department of Medical Biotechnologies, University of Siena, Siena, Italy
| | - Giulio Mazzarotti
- Department of Medical Biotechnologies, University of Siena, Siena, Italy
| | - Milena Dell'Aquila
- Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, USA
| | - Angela Altieri
- Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, USA
| | - Antonella Caporaso
- Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, USA
| | - Cristin Roma
- Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori-Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)-Fondazione G. Pascale, Napoli, Italy
| | - Laura Marra
- Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori-Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)-Fondazione G. Pascale, Napoli, Italy
| | - Silvia Boffo
- Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, USA
| | - Paola Indovina
- Sbarro Research Health Organization, Candiolo, Torino, Italy
| | - Michelino De Laurentiis
- Breast Unit, Istituto Nazionale Tumori-Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)-Fondazione G. Pascale, Napoli, Italy
| | - Antonio Giordano
- Department of Medical Biotechnologies, University of Siena, Siena, Italy.
- Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, USA.
| |
Collapse
|
2
|
Barone D, Iannuzzi CA, Forte IM, Ragosta MC, Cuomo M, Dell’Aquila M, Altieri A, Caporaso A, Camerlingo R, Rigano MM, Monti DM, Barone A, Imbimbo P, Frusciante L, Monda M, D’Angelo M, De Laurentiis M, Giordano A, Alfano L. The hydrophilic extract from a new tomato genotype (named DHO) kills cancer cell lines through the modulation of the DNA damage response induced by Campthotecin treatment. Front Oncol 2023; 13:1117262. [PMID: 37409248 PMCID: PMC10318356 DOI: 10.3389/fonc.2023.1117262] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2022] [Accepted: 04/13/2023] [Indexed: 07/07/2023] Open
Abstract
Introduction DNA double-strand breaks are the most toxic lesions repaired through the non-homologous and joining (NHEJ) or the homologous recombination (HR), which is dependent on the generation of single-strand tails, by the DNA end resection mechanism. The resolution of the HR intermediates leads to error-free repair (Gene Conversion) or the mutagenic pathways (Single Strand Annealing and Alternative End-Joining); the regulation of processes leading to the resolution of the HR intermediates is not fully understood. Methods Here, we used a hydrophilic extract of a new tomato genotype (named DHO) in order to modulate the Camptothecin (CPT) DNA damage response. Results We demonstrated increased phosphorylation of Replication Protein A 32 Serine 4/8 (RPA32 S4/8) protein in HeLa cells treated with the CPT in combination with DHO extract with respect to CPT alone. Moreover, we pointed out a change in HR intermediates resolution from Gene Conversion to Single Strand Annealing through the modified DNA repair protein RAD52 homolog (RAD52), DNA excision repair protein ERCC-1 (ERCC1) chromatin loading in response to DHO extract, and CPT co-treatment, with respect to the vehicle. Finally, we showed an increased sensitivity of HeLa cell lines to DHO extract and CPT co-treatment suggesting a possible mechanism for increasing the efficiency of cancer therapy. Discussion We described the potential role of DHO extract in the modulation of DNA repair, in response to Camptothecin treatment (CPT), favoring an increased sensitivity of HeLa cell lines to topoisomerase inhibitor therapy.
Collapse
Affiliation(s)
- Daniela Barone
- Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori-Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)-Fondazione G. Pascale, Napoli, Italy
| | - Carmelina Antonella Iannuzzi
- Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori-Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)-Fondazione G. Pascale, Napoli, Italy
| | - Iris Maria Forte
- Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori-Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)-Fondazione G. Pascale, Napoli, Italy
| | - Maria Carmen Ragosta
- Department of Medicine, Surgery and Neuroscience, University of Siena and Istituto Toscana Tumori (ITT), Siena, Italy
| | - Maria Cuomo
- Department of Medicine, Surgery and Neuroscience, University of Siena and Istituto Toscana Tumori (ITT), Siena, Italy
| | - Milena Dell’Aquila
- Department of Medicine, Surgery and Neuroscience, University of Siena and Istituto Toscana Tumori (ITT), Siena, Italy
| | - Angela Altieri
- Department of Medicine, Surgery and Neuroscience, University of Siena and Istituto Toscana Tumori (ITT), Siena, Italy
| | - Antonella Caporaso
- Department of Medicine, Surgery and Neuroscience, University of Siena and Istituto Toscana Tumori (ITT), Siena, Italy
| | - Rosa Camerlingo
- Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori-Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)-Fondazione G. Pascale, Napoli, Italy
| | - Maria Manuela Rigano
- Department of Agricultural Sciences, University of Naples Federico II, Naples, Italy
| | - Daria Maria Monti
- Department of Chemical Sciences, University of Naples Federico II, Naples, Italy
| | - Amalia Barone
- Department of Agricultural Sciences, University of Naples Federico II, Naples, Italy
| | - Paola Imbimbo
- Department of Chemical Sciences, University of Naples Federico II, Naples, Italy
| | - Luigi Frusciante
- Department of Agricultural Sciences, University of Naples Federico II, Naples, Italy
| | - Marcellino Monda
- Unit of Dietetics and Sports Medicine, Department of Experimental Medicine, Section of Human Physiology, Università degli Studi della Campania “Luigi Vanvitelli”, Naples, Italy
| | - Margherita D’Angelo
- Unit of Dietetics and Sports Medicine, Department of Experimental Medicine, Section of Human Physiology, Università degli Studi della Campania “Luigi Vanvitelli”, Naples, Italy
| | - Michelino De Laurentiis
- Department of Breast and Thoracic Oncology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Napoli, Italy
| | - Antonio Giordano
- Department of Medicine, Surgery and Neuroscience, University of Siena and Istituto Toscana Tumori (ITT), Siena, Italy
- Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, United States
| | - Luigi Alfano
- Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori-Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)-Fondazione G. Pascale, Napoli, Italy
| |
Collapse
|
3
|
Alfano L, Peck A, Iammarino M, Patel S, Reash N, Almomen M, Mendell J, Sabo B, Long A, Pietruszewski L, Lowes L, Peck N. P.179 Clinical trial readiness and validation of onsite and remote evaluation in valosin containing protein-associated multisystem proteinopathy. Neuromuscul Disord 2022. [DOI: 10.1016/j.nmd.2022.07.317] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
4
|
Murphy L, Alfano L, Brazzo K, Johnson N, Laurent J, Mathews K, Thiele S, Vissing J, Walter M, Woods L, Ørstavik K, Straub V. P.175 Global FKRP registry - the research database for limb girdle muscular dystrophy R9 (2I). Neuromuscul Disord 2022. [DOI: 10.1016/j.nmd.2022.07.313] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
5
|
Rodino-Klapac L, Pozsgai E, Lewis S, Griffin D, Meadows A, Lehman K, Church K, Reash N, Iammarino M, Sabo B, Alfano L, Lowes L, Neuhaus S, Li X, Mendell J. P.170 Safety, β-sarcoglycan expression, and functional outcomes from systemic gene transfer of bidridistrogene xeboparvovec in limb-girdle muscular dystrophy type 2E/R4. Neuromuscul Disord 2022. [DOI: 10.1016/j.nmd.2022.07.308] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
6
|
Lowes L, Iammarino M, Reash N, Giblin K, Hu L, Yu L, Wang S, Alfano L, Mendell J. P.64 Validity of remote evaluation of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy. Neuromuscul Disord 2022. [DOI: 10.1016/j.nmd.2022.07.112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
7
|
James M, Dressman HG, Hilsden H, Rufibach L, Human A, Duong T, Maron E, DeWolf B, Rose K, Siener C, Thiele S, Práxedes NSA, Canal A, Holsten S, Sakamoto C, Pedrosa-Hernández I, Bello L, Alfano L, Lowes LP, Straub V, Mayhew A. P.162 Clinical outcome study of dysferlinopathy: Performance of upper limb entry item to predict forced vital capacity in dysferlinopathy (LGMDR2). Neuromuscul Disord 2022. [DOI: 10.1016/j.nmd.2022.07.300] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/06/2023]
|
8
|
Mendell J, Shieh P, Sahenk Z, Lehman K, Lowes L, Reash N, Iammarino M, Alfano L, Powers B, Woods J, Skura C, Mao H, Staudt L, Potter R, Griffin D, Lewis S, Hu L, Upadhyay S, Singh T, Rodino-Klapac L. CLINICAL TRIAL HIGHLIGHTS. Neuromuscul Disord 2021. [DOI: 10.1016/j.nmd.2021.07.383] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
9
|
Mendell J, Sahenk Z, Lehman K, Nease C, Lowes L, Reash N, Iammarino M, Alfano L, Vaiea J, Lewis S, Church K, Shell R, Potter R, Griffin D, Pozsgai E, Hogan M, Rodino-Klapac L. DMD - TREATMENT. Neuromuscul Disord 2021. [DOI: 10.1016/j.nmd.2021.07.164] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
10
|
Korb M, Peck A, Berger K, James M, Ghoshal N, Healzer E, Henchcliffe C, Khan S, Mammen P, Patel S, Pfeffer G, Ralston S, Roy B, Seeley B, Swenson A, Mozaffar T, Weihl C, Kimonis V, Alfano L. REGISTRIES AND CARE OF NMD. Neuromuscul Disord 2021. [DOI: 10.1016/j.nmd.2021.07.372] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
11
|
Iammarino M, Alfano L, James M, Mozaffar T, Mathews K, Weihl C, Leung D, Statland J, Kang P, Wicklund M, Lowes L, Vissing J, Manera JD, Ganesh V, Holmberg B, DeSpain E, Bates K, Sproule D, Johnson N, GRASP Consortium. LGMD. Neuromuscul Disord 2021. [DOI: 10.1016/j.nmd.2021.07.218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
12
|
Lombardi R, Sonego M, Pucci B, Addi L, Iannelli F, Capone F, Alfano L, Roca MS, Milone MR, Moccia T, Costa A, Di Gennaro E, Bruzzese F, Baldassarre G, Budillon A. HSP90 identified by a proteomic approach as druggable target to reverse platinum resistance in ovarian cancer. Mol Oncol 2021; 15:1005-1023. [PMID: 33331136 PMCID: PMC8024727 DOI: 10.1002/1878-0261.12883] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2020] [Revised: 11/05/2020] [Accepted: 12/14/2020] [Indexed: 12/23/2022] Open
Abstract
Acquired resistance to platinum (Pt)-based therapies is an urgent unmet need in the management of epithelial ovarian cancer (EOC) patients. Here, we characterized by an unbiased proteomics method three isogenic EOC models of acquired Pt resistance (TOV-112D, OVSAHO, and MDAH-2774). Using this approach, we identified several differentially expressed proteins in Pt-resistant (Pt-res) compared to parental cells and the chaperone HSP90 as a central hub of these protein networks. Accordingly, up-regulation of HSP90 was observed in all Pt-res cells and heat-shock protein 90 alpha isoform knockout resensitizes Pt-res cells to cisplatin (CDDP) treatment. Moreover, pharmacological HSP90 inhibition using two different inhibitors [17-(allylamino)-17-demethoxygeldanamycin (17AAG) and ganetespib] synergizes with CDDP in killing Pt-res cells in all tested models. Mechanistically, genetic or pharmacological HSP90 inhibition plus CDDP -induced apoptosis and increased DNA damage, particularly in Pt-res cells. Importantly, the antitumor activities of HSP90 inhibitors (HSP90i) were confirmed both ex vivo in primary cultures derived from Pt-res EOC patients ascites and in vivo in a xenograft model. Collectively, our data suggest an innovative antitumor strategy, based on Pt compounds plus HSP90i, to rechallenge Pt-res EOC patients that might warrant further clinical evaluation.
Collapse
Affiliation(s)
- Rita Lombardi
- Experimental Pharmacology Unit‐Laboratories of Naples and Mercogliano (AV)Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale” – IRCCSNaplesItaly
| | - Maura Sonego
- Division of Molecular OncologyCentro di Riferimento Oncologico di Aviano (CRO)IRCCSAvianoItaly
| | - Biagio Pucci
- Experimental Pharmacology Unit‐Laboratories of Naples and Mercogliano (AV)Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale” – IRCCSNaplesItaly
| | - Laura Addi
- Experimental Pharmacology Unit‐Laboratories of Naples and Mercogliano (AV)Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale” – IRCCSNaplesItaly
| | - Federica Iannelli
- Experimental Pharmacology Unit‐Laboratories of Naples and Mercogliano (AV)Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale” – IRCCSNaplesItaly
| | - Francesca Capone
- Experimental Pharmacology Unit‐Laboratories of Naples and Mercogliano (AV)Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale” – IRCCSNaplesItaly
| | - Luigi Alfano
- Cell Biology and Biotherapy UnitIstituto Nazionale Tumori ‐ IRCCS, Fondazione G. PascaleNaplesItaly
| | - Maria Serena Roca
- Experimental Pharmacology Unit‐Laboratories of Naples and Mercogliano (AV)Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale” – IRCCSNaplesItaly
| | - Maria Rita Milone
- Experimental Pharmacology Unit‐Laboratories of Naples and Mercogliano (AV)Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale” – IRCCSNaplesItaly
| | - Tania Moccia
- Experimental Pharmacology Unit‐Laboratories of Naples and Mercogliano (AV)Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale” – IRCCSNaplesItaly
| | - Alice Costa
- Division of Molecular OncologyCentro di Riferimento Oncologico di Aviano (CRO)IRCCSAvianoItaly
- University of TriesteItaly
| | - Elena Di Gennaro
- Experimental Pharmacology Unit‐Laboratories of Naples and Mercogliano (AV)Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale” – IRCCSNaplesItaly
| | - Francesca Bruzzese
- Experimental Pharmacology Unit‐Laboratories of Naples and Mercogliano (AV)Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale” – IRCCSNaplesItaly
| | - Gustavo Baldassarre
- Division of Molecular OncologyCentro di Riferimento Oncologico di Aviano (CRO)IRCCSAvianoItaly
| | - Alfredo Budillon
- Experimental Pharmacology Unit‐Laboratories of Naples and Mercogliano (AV)Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale” – IRCCSNaplesItaly
| |
Collapse
|
13
|
Mendell J, Sahenk Z, Lehman K, Nease C, Lowes L, Miller N, Iammarino M, Alfano L, Vaiea J, Al-Zaidy S, Lewis S, Church K, Shell R, Potter R, Griffin D, Pozsgai E, Hogan M, Rodino-Klapac L. DMD – THERAPY. Neuromuscul Disord 2020. [DOI: 10.1016/j.nmd.2020.08.277] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
14
|
Iammarino M, Powers B, Miller N, Shannon K, Alfano L, Lowes L. SMA - CLINICAL. Neuromuscul Disord 2020. [DOI: 10.1016/j.nmd.2020.08.094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
15
|
Powers B, Alcock L, Iammarino M, James M, Miller N, Hilsden H, Shannon K, Lowes L, Alfano L. OUTCOME MEASURES. Neuromuscul Disord 2020. [DOI: 10.1016/j.nmd.2020.08.250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
16
|
Mendell J, Shell R, Lehman K, McColly M, Lowes L, Alfano L, Miller N, Iammarino M, Church K, Ogrinc F, Ouyang H, Kernbauer E, Joshi S, Sproule D, Meriggioli M, Feltner D, Al-Zaidy S. SMA – THERAPY. Neuromuscul Disord 2020. [DOI: 10.1016/j.nmd.2020.08.260] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
17
|
Alfano L, James M, Miller N, Muni-Lofra R, Iammarino M, Moat D, Powers B, Sodhi J, McCallum M, Shannon K, Eagle M, Mayhew A, Lowes L. OUTCOME MEASURES. Neuromuscul Disord 2020. [DOI: 10.1016/j.nmd.2020.08.244] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
18
|
Iammarino M, Miller N, Alfano L, Powers B, Shannon K, Connolly A, Waldrop M, Tsao C, Sahenk Z, Flanigan K, Mendell J, Lowes L. OUTCOME MEASURES. Neuromuscul Disord 2020. [DOI: 10.1016/j.nmd.2020.08.251] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
19
|
Miller N, Iammarino M, Alfano L, Powers B, Shannon K, Nease C, Lehman K, Mendell J, Lowes L. LIMB GIRDLE MUSCULAR DYSTROPHIES. Neuromuscul Disord 2020. [DOI: 10.1016/j.nmd.2020.08.146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
20
|
Lowes L, Miller N, Iammarino M, Powers B, Shannon K, Alfano L. OUTCOME MEASURES. Neuromuscul Disord 2020. [DOI: 10.1016/j.nmd.2020.08.243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
21
|
Altieri A, Dell’Aquila M, Pentimalli F, Giordano A, Alfano L. SMART (Single Molecule Analysis of Resection Tracks) Technique for Assessing DNA end-Resection in Response to DNA Damage. Bio Protoc 2020; 10:e3701. [PMID: 33659366 PMCID: PMC7842315 DOI: 10.21769/bioprotoc.3701] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2019] [Revised: 05/28/2020] [Accepted: 06/17/2020] [Indexed: 11/02/2022] Open
Abstract
DNA double strand breaks (DSBs) are among the most toxic lesions affecting genome integrity. DSBs are mainly repaired through non-homologous end joining (NHEJ) and homologous recombination (HR). A crucial step of the HR process is the generation, through DNA end-resection, of a long 3' single-strand DNA stretch, necessary to prime DNA synthesis using a homologous region as a template, following DNA strand invasion. DNA end resection inhibits NHEJ and triggers homology-directed DSB repair, ultimately guaranteeing a faithful DNA repair. Established methods to evaluate the DNA end-resection process are the immunofluorescence analysis of the phospho-S4/8 RPA32 protein foci, a marker of DNA end-resection, or of the phospho-S4/8 RPA32 protein levels by Western blot. Recently, the Single Molecule Analysis of Resection Tracks (SMART) has been described as a reliable method to visualize, by immunofluorescence, the long 3' single-strand DNA tails generated upon cell treatment with a S-phase specific DNA damaging agent (such as camptothecin). Then, DNA tract lengths can be measured through an image analysis software (such as Photoshop), to evaluate the processivity of the DNA end-resection machinery. The preparation of DNA fibres is performed in non-denaturing conditions so that the immunofluorescence detects only the specific long 3' single-strand DNA tails, generated from DSB processing.
Collapse
Affiliation(s)
- Angela Altieri
- Department of Medicine, Surgery and Neuroscience, University of Siena and Istituto Toscana Tumori (ITT), Siena, Italy
| | - Milena Dell’Aquila
- Department of Medicine, Surgery and Neuroscience, University of Siena and Istituto Toscana Tumori (ITT), Siena, Italy
| | - Francesca Pentimalli
- Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori IRCCS, Fondazione G. Pascale, Naples, Italy
| | - Antonio Giordano
- Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori IRCCS, Fondazione G. Pascale, Naples, Italy
- Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Department of Biology, Temple University, Philadelphia PA, USA
| | - Luigi Alfano
- Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori IRCCS, Fondazione G. Pascale, Naples, Italy
| |
Collapse
|
22
|
Alfano L, Caporaso A, Altieri A, Dell'Aquila M, Landi C, Bini L, Pentimalli F, Giordano A. Depletion of the RNA binding protein HNRNPD impairs homologous recombination by inhibiting DNA-end resection and inducing R-loop accumulation. Nucleic Acids Res 2019; 47:4068-4085. [PMID: 30799487 PMCID: PMC6486545 DOI: 10.1093/nar/gkz076] [Citation(s) in RCA: 36] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2018] [Revised: 01/24/2019] [Accepted: 02/01/2019] [Indexed: 12/12/2022] Open
Abstract
DNA double strand break (DSB) repair through homologous recombination (HR) is crucial to maintain genome stability. DSB resection generates a single strand DNA intermediate, which is crucial for the HR process. We used a synthetic DNA structure, mimicking a resection intermediate, as a bait to identify proteins involved in this process. Among these, LC/MS analysis identified the RNA binding protein, HNRNPD. We found that HNRNPD binds chromatin, although this binding occurred independently of DNA damage. However, upon damage, HNRNPD re-localized to γH2Ax foci and its silencing impaired CHK1 S345 phosphorylation and the DNA end resection process. Indeed, HNRNPD silencing reduced: the ssDNA fraction upon camptothecin treatment; AsiSI-induced DSB resection; and RPA32 S4/8 phosphorylation. CRISPR/Cas9-mediated HNRNPD knockout impaired in vitro DNA resection and sensitized cells to camptothecin and olaparib treatment. We found that HNRNPD interacts with the heterogeneous nuclear ribonucleoprotein SAF-A previously associated with DNA damage repair. HNRNPD depletion resulted in an increased amount of RNA:DNA hybrids upon DNA damage. Both the expression of RNase H1 and RNA pol II inhibition recovered the ability to phosphorylate RPA32 S4/8 in HNRNPD knockout cells upon DNA damage, suggesting that RNA:DNA hybrid resolution likely rescues the defective DNA damage response of HNRNPD-depleted cells.
Collapse
Affiliation(s)
- Luigi Alfano
- Oncology Research Center of Mercogliano (CROM); Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli, Italia
| | - Antonella Caporaso
- Department of Medical Biotechnologies, University of Siena, Siena, Italia.,Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, USA
| | - Angela Altieri
- Department of Medical Biotechnologies, University of Siena, Siena, Italia
| | - Milena Dell'Aquila
- Department of Medical Biotechnologies, University of Siena, Siena, Italia
| | - Claudia Landi
- Department of Life Sciences, University of Siena, Siena, Italia
| | - Luca Bini
- Department of Life Sciences, University of Siena, Siena, Italia
| | - Francesca Pentimalli
- Oncology Research Center of Mercogliano (CROM); Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli, Italia
| | - Antonio Giordano
- Department of Medical Biotechnologies, University of Siena, Siena, Italia.,Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, USA
| |
Collapse
|
23
|
Alfano L, Miller N, Iammarino M, Lowes L. P.215Utility of functional outcomes in adults with spinal muscular atrophy. Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.329] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
24
|
Mah M, Slawinski M, Cripe L, Camino E, Al-Zaidy S, Hassan S, Jackson J, Lowes L, Iammarino M, Miller N, Alfano L, Lehman K, Mendell J, Hor K. DMD CLINICAL. Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.372] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
25
|
Mendell J, Shell R, Lehman K, McColly M, Lowes L, Alfano L, Miller N, Iammarino M, Church K, Ogrinc F, Ouyang H, Kernbauer E, Shah S, L'Italien J, Sproule D, Feltner D, Al-Zaidy S. P.351Gene-replacement therapy (GRT) in spinal muscular atrophy type 1 (SMA1): long-term follow-up from the onasemnogene abeparvovec phase 1/2a clinical trial. Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.513] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
26
|
Alfano L, Miller N, Iammarino M, Lowes L. P.193The neuromuscular gross motor outcome as an outcome measure in spinal muscular atrophy. Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.248] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
27
|
Miller N, Alfano L, Iammarino M, Moore-Clingenpeel M, Tsao C, Waldrop M, Flanigan K, Mendell J, Lowes L. EP.89Clinical trials in young boys and infants with DMD: how do you handle maturation? Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.495] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
28
|
Lowes L, Alfano L, Chen D, Nelson L, Miller N, Iammarino M, McColly M, Mendell J, Rust S. P.214Presymptomatic spinal muscular atrophy: reality or myth? Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.328] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
29
|
Waldrop M, Lowes L, Toops J, Alfano L, Miller N, Iammarino M, Kotha K, Paul G, Moore-Clingenpeel M, Tsao C, Noritz G, Shell R, Flanigan K. P.365Clinical outcomes in patients with spinal muscular atrophy type 1, 2 or 3 after 1 year of nusinersen therapy. Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.527] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
30
|
Jackson J, Leslie C, Cotto J, Korth C, Mah M, Hor K, Cripe L, Camino E, Al-Zaidy S, Hassan S, Vannatta K, Lowes L, Iammarino M, Miller N, Alfano L, Lehman K, Mendell J. DMD BRAIN. Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.392] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
31
|
James M, Fernández-Torrón R, Mayhew A, Alfano L, Muni-Lofra R, Duong T, Maron E, Hutchence M, Vandervelde B, Mendez B, Holsten S, Sakamoto C, Pedrosa Belmonte I, Thiele S, Canal A, Semplicini C, Seiner C, Lowes L, Straub V, Diaz-Manera J. P.184Clinical outcome study for dysferlinopathy: a longitudinal examination of the upper limb involvement using physiotherapy outcome measures and T1w MRI. Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.239] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
32
|
Iammarino M, Miller N, Alfano L, Lehman K, Rodino-Klapac L, Mendell J, Lowes L. P.174Establishing divergent phenotypes in limb girdle muscular dystrophies. Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.229] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
33
|
Montagna R, Canonico R, Alfano L, Bucci E, Boffo S, Staiano L, Fulco B, D'Andrea E, Nicola A, Maiorano P, D'Angelo C, Chirico A, Nicola A, Giordano A. Genomic analysis reveals association of specific SNPs with athletic performance and susceptibility to injuries in professional soccer players. J Cell Physiol 2019; 235:2139-2148. [DOI: 10.1002/jcp.29118] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2019] [Accepted: 07/17/2019] [Indexed: 12/14/2022]
Affiliation(s)
| | - Raffaele Canonico
- Unità Operativa Complessa di Dietetica, Medicina dello Sport e Benessere Psico‐Fisico Università degli Studi della Campania Luigi Vanvitelli Naples Italy
| | - Luigi Alfano
- Cell Biology and Biotherapy Unit Istituto Nazionale Tumori ‐ IRCCS, Fondazione G. Pascale Naples Italy
| | - Enrico Bucci
- Sbarro Health Research Organization Wayne Pennsylvania
| | - Silvia Boffo
- Sbarro Health Research Organization Wayne Pennsylvania
| | - Leopoldo Staiano
- Laboratory of Cellular and Developmental Biology Stazione Zoologica Anton Dohrn Naples Italy
| | - Beniamino Fulco
- Department of Medical Biotechnologies University of Siena Italy
| | | | | | | | | | - Andrea Chirico
- Sbarro Health Research Organization Wayne Pennsylvania
- Department of Psychology of Development and Socialization Processes “Sapienza” University of Rome Italy
| | | | - Antonio Giordano
- Sbarro Health Research Organization Wayne Pennsylvania
- Department of Medical Biotechnologies University of Siena Italy
| |
Collapse
|
34
|
Verdura V, Di Pace B, Concilio M, Guastafierro A, Fiorillo G, Alfano L, Nicoletti GF, Savastano C, Cascone AM, Rubino C. A new case of radiation-induced breast angiosarcoma. Int J Surg Case Rep 2019; 60:152-155. [PMID: 31228777 PMCID: PMC6597493 DOI: 10.1016/j.ijscr.2019.06.006] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2019] [Revised: 05/25/2019] [Accepted: 06/07/2019] [Indexed: 11/30/2022] Open
Abstract
A biopsy of any suspicious breast skin lesion after radiotherapy is recommended. Patients with clinical anomalies post-breast cancer surgery and RT need attention. The Angiosarcoma was cured due to surgery and high-dose neoadjuvant chemotherapy. A correct 6 month follow-up is needed: check-ups, chest X-rays and ultrasound. The survival of the patient suggests possible ways to manage this rare tumour type.
Introduction Radiation-induced breast angiosarcoma is a severe but rare late complication in the breast-preserving management of breast cancer through surgery and radiotherapy. Often the initial diagnosis is complex given its relatively anodyne nature and the fact that it usually presents in the form of typically multifocal reddish-purple papular skin lesions. Presentation of the case We describe the clinical and pathologic findings of a 79-year-old woman, who developed a radiation-induced breast angiosarcoma after around 8 years. She initially refused a mastectomy leading to an adaptation in the management of this cancer. Discussion The average latency of secondary angiosarcoma of the breast following radiation therapy is around six years. Breast angiosarcoma is typically considered to affect the dermis, and is therefore cutaneous in origin. An incisional biopsy of the discoloured skin and underlying mass is necessary. The treatment is surgical resection. The role of chemotherapy has not been clearly defined. Most data originate from retrospective case series studies suggesting that angiosarcomas are relatively sensitive to taxanes and anthracyclines. Conclusion The preferred treatment is always aggressive surgical removal and, as our atypical clinical case suggests, neoadjuvant chemotherapy in very high doses is also needed. A biopsy of any suspicious breast skin lesion after radiotherapy is recommended. Despite the treatment challenges, our case provides enlightening details on the management of such a rare cancer even when faced with unplanned events which do not always allow for a textbook approach.
Collapse
Affiliation(s)
- Vincenzo Verdura
- Multidisciplinary Department of Medical-Surgical and Dental Specialties, Plastic Surgery Unit, Università degli Studi della Campania "Luigi Vanvitelli", Naples, Italy.
| | - Bruno Di Pace
- Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana" PhD School in Translational Medicine of Development and Active Aging, Università degli Studi di Salerno, Salerno, Italy
| | - Marina Concilio
- Department of Medicine, Surgery and Dentistry, Plastic Surgery Unit, Università degli Studi di Salerno, Salerno, Italy
| | - Antonio Guastafierro
- Multidisciplinary Department of Medical-Surgical and Dental Specialties, Plastic Surgery Unit, Università degli Studi della Campania "Luigi Vanvitelli", Naples, Italy
| | - Gabriella Fiorillo
- A.O.U. San Giovanni di Dio e Ruggi D'Aragona, via San Leonardo, Salerno, Italy
| | - Luigi Alfano
- A.O.U. San Giovanni di Dio e Ruggi D'Aragona, via San Leonardo, Salerno, Italy
| | - Giovanni Francesco Nicoletti
- Multidisciplinary Department of Medical-Surgical and Dental Specialties, Plastic Surgery Unit, Università degli Studi della Campania "Luigi Vanvitelli", Naples, Italy
| | | | - Anna Maria Cascone
- A.O.U. San Giovanni di Dio e Ruggi D'Aragona, via San Leonardo, Salerno, Italy
| | - Corrado Rubino
- Department of Medicine, Surgery and Dentistry, Plastic Surgery Unit, Università degli Studi di Salerno, Salerno, Italy; Plastic Surgery Unit, Department of Surgery, Microsurgery and Medical Sciences, University Hospital Trust, Università degli Studi di Sassari, Sassari, Italy
| |
Collapse
|
35
|
Shell R, Al-Zaidy S, Arnold W, Rodino-Klapac L, Prior T, Kotha K, Paul G, Lowes L, Alfano L, Berry K, Church K, Kissel J, Nagendran S, Ogrinc F, Sproule D, Wells C, Meyer K, Likhite S, Kaspar B, Mendell J. SMA THERAPIES I. Neuromuscul Disord 2018. [DOI: 10.1016/j.nmd.2018.06.206] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
36
|
Flanigan K, Chicoine L, Cheatham J, Cheatham S, Simmons T, Lowes L, Iammarino M, Miller N, Alfano L, Rinaldi F, Waldrop M, Zygmunt D, Xu R, Martin P. DMD CLINICAL THERAPIES II. Neuromuscul Disord 2018. [DOI: 10.1016/j.nmd.2018.06.159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
37
|
Mendell J, Al-Zaidy S, Shell R, Arnold W, Rodino-Klapac L, Prior T, Lowes L, Alfano L, Berry K, Church K, Kissel J, Nagendran S, Italien J, Sproule D, Wells C, Burghes A, Foust K, Meyer K, Likhite S, Kaspar B. SMA THERAPIES I. Neuromuscul Disord 2018. [DOI: 10.1016/j.nmd.2018.06.205] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
38
|
Miller N, Lowes L, James M, Alfano L, Mayhew A, Maron E, Gee R, Harman M, Duong T, Vandervelde B, Siener C, Thiele S, Mendez B, Canal A, Sakamoto C, Holsten S, Pedrosa Belmonte I, Semplicini C, Straub V. LIMB-GIRDLE MUSCULAR DYSTROPHY I. Neuromuscul Disord 2018. [DOI: 10.1016/j.nmd.2018.06.038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
39
|
Lowes L, Alfano L, Iammarino M, Miller N, Menier M, Cardenas J, Sproule D, Nagendran S, Al-Zaidy S, Mendell J. SMA THERAPIES I. Neuromuscul Disord 2018. [DOI: 10.1016/j.nmd.2018.06.207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
40
|
Alfano L, Lowes L, Al-Zaidy S, Shell R, Arnold W, Rodino-Klapac L, Prior T, Berry K, Church K, Kissel J, Nagendran S, Italien J, Sproule D, Wells C, Burghes A, Foust K, Meyer K, Likhite S, Kaspar B, Mendell J. SMA THERAPIES I. Neuromuscul Disord 2018. [DOI: 10.1016/j.nmd.2018.06.208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
41
|
Alfano L, Miller N, Iammarino M, Berry K, Moore-Clingenpeel M, Dugan M, Al-Zaidy S, Tsao C, Rodino-Klapac L, Waldrop M, Flanigan K, Mendell J, Lowes L. DUCHENNE MUSCULAR DYSTROPHY - PHYSIOTHERAPY. Neuromuscul Disord 2018. [DOI: 10.1016/j.nmd.2018.06.365] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
42
|
Alfano L, Miller N, Iammarino M, Moore-Clingenpeel M, Lowes S, Dugan M, Waldrop M, Flanigan K, Noritz G, Tsao C, Al Zaidy S, Kissel J, Lowes L. SMA CLINICAL DATA, OUTCOME MEASURES AND REGISTRIES. Neuromuscul Disord 2018. [DOI: 10.1016/j.nmd.2018.06.117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
43
|
Pentimalli F, Forte IM, Esposito L, Indovina P, Iannuzzi CA, Alfano L, Costa C, Barone D, Rocco G, Giordano A. RBL2/p130 is a direct AKT target and is required to induce apoptosis upon AKT inhibition in lung cancer and mesothelioma cell lines. Oncogene 2018; 37:3657-3671. [PMID: 29606701 DOI: 10.1038/s41388-018-0214-3] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2017] [Revised: 12/30/2017] [Accepted: 02/03/2018] [Indexed: 12/29/2022]
Abstract
The retinoblastoma (RB) protein family includes RB1/p105, RBL1/p107, and RBL2/p130, which are key factors in cell-cycle regulation and stand at the crossroads of multiple pathways dictating cell fate decisions. The role of RB proteins in apoptosis is controversial because they can inhibit or promote apoptosis depending on the context, on the apoptotic stimuli and on their intrinsic status, impacting on the response to antitumoral treatments. Here we identified RBL2/p130 as a direct substrate of the AKT kinase, a key antiapoptotic factor hyperactive in multiple cancer types. We showed that RBL2/p130 and AKT1 physically interact and AKT phosphorylates RBL2/p130 Ser941, located in the pocket domain, but not when this residue is mutated into Ala. We found that pharmacological inhibition of AKT, through the highly selective AKT inhibitor VIII (AKTiVIII), impairs RBL2/p130 Ser941 phosphorylation and increases RBL2/p130 stability, mRNA expression and nuclear levels in both lung cancer and mesothelioma cell lines, mirroring the more extensively studied effects on the p27 cell-cycle inhibitor. Consistently, AKT inhibition reduced cell viability, induced cell accumulation in G0/G1, and triggered apoptosis, which proved to be largely dependent on RBL2/p130 itself, as shown upon RBL2/p130 silencing. AKT inhibition induced RBL2/p130-dependent apoptosis also in HEK-293 cells, in which re-expression of a short hairpin-resistant RBL2/p130 was able to rescue AKTiVIII-induced apoptosis upon RBL2/p130 silencing. Our data also showed that the combination of AKT and cyclin-dependent kinases (CDK) inhibitors, which converge on the re-activation of RBL2/p130 antitumoral potential, could be a promising anticancer strategy.
Collapse
Affiliation(s)
- Francesca Pentimalli
- Oncology Research Center of Mercogliano (CROM), Istituto Nazionale Tumori - IRCCS, "Fondazione G. Pascale", 80131, Napoli, Italy.
| | - Iris M Forte
- Oncology Research Center of Mercogliano (CROM), Istituto Nazionale Tumori - IRCCS, "Fondazione G. Pascale", 80131, Napoli, Italy
| | - Luca Esposito
- Oncology Research Center of Mercogliano (CROM), Istituto Nazionale Tumori - IRCCS, "Fondazione G. Pascale", 80131, Napoli, Italy
| | - Paola Indovina
- Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Scienceand Technology, Temple University, Philadelphia, PA, 19122, USA
| | - Carmelina A Iannuzzi
- Oncology Research Center of Mercogliano (CROM), Istituto Nazionale Tumori - IRCCS, "Fondazione G. Pascale", 80131, Napoli, Italy.,Department of Medicine, Surgery and Neuroscience, University of Siena, 53100, Siena, Italy
| | - Luigi Alfano
- Oncology Research Center of Mercogliano (CROM), Istituto Nazionale Tumori - IRCCS, "Fondazione G. Pascale", 80131, Napoli, Italy
| | - Caterina Costa
- Oncology Research Center of Mercogliano (CROM), Istituto Nazionale Tumori - IRCCS, "Fondazione G. Pascale", 80131, Napoli, Italy
| | - Daniela Barone
- Oncology Research Center of Mercogliano (CROM), Istituto Nazionale Tumori - IRCCS, "Fondazione G. Pascale", 80131, Napoli, Italy.,Department of Medicine, Surgery and Neuroscience, University of Siena, 53100, Siena, Italy
| | - Gaetano Rocco
- Division of Thoracic Surgery, Department of Thoracic Surgery and Oncology, Istituto Nazionale Tumori "Fondazione G. Pascale"; IRCCS, 80131, Napoli, Italy
| | - Antonio Giordano
- Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Scienceand Technology, Temple University, Philadelphia, PA, 19122, USA. .,Department of Medicine, Surgery and Neuroscience, University of Siena, 53100, Siena, Italy.
| |
Collapse
|
44
|
Alfano L, Costa C, Caporaso A, Antonini D, Giordano A, Pentimalli F. HUR protects NONO from degradation by mir320, which is induced by p53 upon UV irradiation. Oncotarget 2018; 7:78127-78139. [PMID: 27816966 PMCID: PMC5363649 DOI: 10.18632/oncotarget.13002] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2016] [Accepted: 10/12/2016] [Indexed: 12/13/2022] Open
Abstract
UV radiations challenge genomic stability and are a recognized cancer risk factor. We previously found that the RNA-binding protein NONO regulates the intra-S phase checkpoint and its silencing impaired HeLa and melanoma cell response to UV-induced DNA damage. Here we investigated the mechanisms underlying NONO regulation upon UVC treatment. We found that UVC rays induce the expression of mir320a, which can indeed target NONO. However, despite mir320a induction, NONO mRNA and protein expression are not affected by UVC. We found through RNA immunoprecipitation that UVC rays induce the ubiquitous RNA-binding protein HUR to bind NONO 5′UTR in a site overlapping mir320a binding site. Both HUR silencing and its pharmacological inhibition induced NONO downregulation following UVC exposure, whereas concomitant mir320a silencing restored NONO stability. UVC-mediated mir320a upregulation is triggered by p53 binding to its promoter, which lies within a region marked by H3K4me3 and H3K27ac signals upon UVC treatment. Silencing mir320a sensitizes cells to DNA damage. Overall our findings reveal a new mechanism whereby HUR protects NONO from mir320-mediated degradation upon UVC exposure and identify a new component within the complex network of players underlying the DNA damage response adding mir320a to the list of p53-regulated targets upon genotoxic stress.
Collapse
Affiliation(s)
- Luigi Alfano
- Oncology Research Center of Mercogliano (CROM), Istituto Nazionale Per Lo Studio E La Cura Dei Tumori "Fondazione Giovanni Pascale", IRCCS, Naples, 80131, Italy
| | - Caterina Costa
- Oncology Research Center of Mercogliano (CROM), Istituto Nazionale Per Lo Studio E La Cura Dei Tumori "Fondazione Giovanni Pascale", IRCCS, Naples, 80131, Italy
| | - Antonella Caporaso
- Department of Medicine, Surgery and Neuroscience, University of Siena and Istituto Toscano Tumori (ITT), Siena, 53100, Italy
| | | | - Antonio Giordano
- Department of Medicine, Surgery and Neuroscience, University of Siena and Istituto Toscano Tumori (ITT), Siena, 53100, Italy.,Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia PA, 19122, USA
| | - Francesca Pentimalli
- Oncology Research Center of Mercogliano (CROM), Istituto Nazionale Per Lo Studio E La Cura Dei Tumori "Fondazione Giovanni Pascale", IRCCS, Naples, 80131, Italy.,Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia PA, 19122, USA
| |
Collapse
|
45
|
|
46
|
Abstract
Current treatment for acute myeloid leukemia (AML) is less than optimal, but increased understanding of disease pathobiology and genomics has led to clinical investigation of novel targeted therapies and rational combinations. Targeting the cyclin-dependent kinase 9 (CDK9) pathway, which is dysregulated in AML, is an attractive approach. Inhibition of CDK9 leads to downregulation of cell survival genes regulated by super enhancers such as MCL-1, MYC, and cyclin D1. As CDK9 inhibitors are nonselective, predictive biomarkers that may help identify patients most likely to respond to CDK9 inhibitors are now being utilized, with the goal of improving efficacy and safety.
Collapse
Affiliation(s)
- Silvia Boffo
- Sbarro Institute for Cancer Research and Molecular Medicine, Department of Biology, Temple University, 1900 N. 12th St., Room 431, Philadelphia, PA 19122-6017 USA
| | - Angela Damato
- Sbarro Institute for Cancer Research and Molecular Medicine, Department of Biology, Temple University, 1900 N. 12th St., Room 431, Philadelphia, PA 19122-6017 USA
- Medical Oncology Unit, Clinical Cancer Centre, IRCCS–Arcispedale S. Maria Nuova, Reggio Emilia, Italy
| | - Luigi Alfano
- Oncology Research Center of Mercogliano (CROM), Istituto Nazionale Per Lo Studio E La Cura Dei Tumori “Fondazione Giovanni Pascale”, IRCCS, Naples, Italy
| | - Antonio Giordano
- Sbarro Institute for Cancer Research and Molecular Medicine, Department of Biology, Temple University, 1900 N. 12th St., Room 431, Philadelphia, PA 19122-6017 USA
- Department of Medicine, Surgery, and Neuroscience, University of Siena, Siena, Italy
| |
Collapse
|
47
|
Alfano L, Caporaso A, Altieri A, Costa C, Forte IM, Iannuzzi CA, Barone D, Esposito L, Giordano A, Pentimalli F. NONO ubiquitination is mediated by FBW7 and GSK3
β
via a degron lost upon chromosomal rearrangement in cancer. J Cell Physiol 2017; 233:4338-4344. [DOI: 10.1002/jcp.26269] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2017] [Accepted: 11/13/2017] [Indexed: 12/14/2022]
Affiliation(s)
- Luigi Alfano
- Oncology Research Center of Mercogliano (CROM), Istituto Nazionale Tumori “Fondazione G. Pascale”IRCCSNapoliItalia
| | - Antonella Caporaso
- Department of Medicine, Surgery and NeuroscienceUniversity of SienaSienaItaly
| | - Angela Altieri
- Department of Medicine, Surgery and NeuroscienceUniversity of SienaSienaItaly
| | - Caterina Costa
- Oncology Research Center of Mercogliano (CROM), Istituto Nazionale Tumori “Fondazione G. Pascale”IRCCSNapoliItalia
| | - Iris M. Forte
- Oncology Research Center of Mercogliano (CROM), Istituto Nazionale Tumori “Fondazione G. Pascale”IRCCSNapoliItalia
| | - Carmelina A. Iannuzzi
- Oncology Research Center of Mercogliano (CROM), Istituto Nazionale Tumori “Fondazione G. Pascale”IRCCSNapoliItalia
| | - Daniela Barone
- Oncology Research Center of Mercogliano (CROM), Istituto Nazionale Tumori “Fondazione G. Pascale”IRCCSNapoliItalia
| | - Luca Esposito
- Oncology Research Center of Mercogliano (CROM), Istituto Nazionale Tumori “Fondazione G. Pascale”IRCCSNapoliItalia
| | - Antonio Giordano
- Oncology Research Center of Mercogliano (CROM), Istituto Nazionale Tumori “Fondazione G. Pascale”IRCCSNapoliItalia
- Department of Medicine, Surgery and NeuroscienceUniversity of SienaSienaItaly
- Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and TechnologyTemple UniversityPhiladelphiaPennsylvania
| | - Francesca Pentimalli
- Oncology Research Center of Mercogliano (CROM), Istituto Nazionale Tumori “Fondazione G. Pascale”IRCCSNapoliItalia
| |
Collapse
|
48
|
Miller N, Alfano L, Flanigan K, Al-Zaidy S, Tsao C, Mendell J, Lowes L. The 100-meter timed test: ability to detect change over time in Duchenne muscular dystrophy. Neuromuscul Disord 2017. [DOI: 10.1016/j.nmd.2017.06.504] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
49
|
Shell R, Al-Zaidy S, Arnold W, Rodino-Klapac L, Prior T, Lowes L, Alfano L, Berry K, Church K, Kissel J, Nagendran S, L'Italien J, Sproule D, Wells C, Burghes A, Foust K, Meyer K, Likhite S, Kaspar B, Mendell J. AVXS-101 phase 1 gene therapy clinical trial in SMA Type 1: decreased need of ventilatory and nutritional support at End-of-Study. Neuromuscul Disord 2017. [DOI: 10.1016/j.nmd.2017.06.413] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
50
|
Alfano L, Berry K, Miller N, Cripe L, Flanigan K, Mendell J, Lowes L. Evaluating the effect of a monetary incentive on performance of the 100-meter timed test in Duchenne muscular dystrophy. Neuromuscul Disord 2016. [DOI: 10.1016/j.nmd.2016.06.364] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|